Direct-to-patient (DTP) readiness assessment

Direct‑to‑patient (DTP) models are increasingly part of how life sciences organizations think about access, affordability, and patient engagement. As pricing pressures, policy dynamics, and patient expectations evolve, direct models are often explored to simplify pathways and retain greater control over the patient experience.

DTP is not one‑size‑fits‑all. Not every asset, indication, or market is positioned to benefit from a direct approach, and when applied without a clear understanding of fit, DTP models can introduce unintended pricing, access, operational, and long‑term value risk.

Acumetis helps life sciences leaders evaluate DTP not as a shortcut, but as a strategic decision. Our direct‑to‑patient readiness assessment provides a structured way to understand whether, where, and how a DTP approach aligns with an asset’s clinical profile, access environment, commercial strategy, and operational realities, before commitments are made.

In just a few minutes, you’ll receive a data-driven readiness score that highlights opportunity areas, strategic gaps, and where DTP can deliver measurable value.

Start the Assessment →   DTP Readiness Assessment

 

What is the DTP readiness assessment tool?

Our direct‑to‑patient readiness assessment is a self‑guided, fact‑based framework designed to clarify if, where, and how a product can succeed in a direct‑to‑patient model. It distills complex market, access, and patient dynamics into a single readiness signal, helping teams make more informed strategic decisions with greater confidence.

A strategic tool for smarter DTP decisions

The question is not whether direct‑to‑patient approaches can increase awareness or attract attention. The question is whether they will meaningfully move the needle for a product and the patients it serves.

Our DTP readiness assessment translates complex market, access, and behavioral considerations into a clear readiness signal, helping teams focus effort where DTP can deliver the most impact by:
→ Evaluate your product’s suitability for DTP engagement
→ Assess high-value opportunities and market constraints
→ Focus your launch and access strategy where DTP can deliver the most impact

In some cases, the results indicate a clear opportunity for broader application. In others, they point toward a more targeted, phased, or hybrid approach.
In every case, the goal is the same: to provide clarity and confidence in the path forward.

Why use the direct‑to‑patient readiness assessment?

Developed by Acumetis, the DTP readiness assessment bridges data, strategy, and patient insight to guide commercialization and access decision‑making. It is designed to help teams move from exploration to evidence, replacing assumptions with clarity.

The assessment is:

  • Strategic, not speculative, grounded in real‑world access, patient, and market frameworks
  • Fast but meaningful, completed in minutes while delivering actionable insight
  • Comprehensive in lens, blending access, behavioral, digital, and operational considerations
  • Scalable in application, relevant across early planning, launch, and in‑line optimization

How the assessment works

Responses are analyzed across four core DTP readiness pillars, each capturing a critical dimension of potential performance. Each pillar is assessed as low, medium, or high, and together they aggregate into a single DTP readiness score that reflects overall opportunity and risk balance.

Feat-AR- DTP Assessment Pillars

 

 

 

 

 

 

 

 

 

 

 

 

This approach allows teams to understand not only where opportunities may exist, but also what trade‑offs and constraints must be addressed for a DTP approach to succeed sustainably.

Assessment inputs

To ensure accuracy, the assessment evaluates multiple parameters that influence DTP success. These inputs allow the algorithm to deliver a readiness profile grounded in real-world access, behavioral, and digital market data.

FEAT-AR- DTP Categories

Your readiness score

Once complete, the tool instantly generates your personalized DTP readiness score. Your score concisely signals where your product stands today and where strategic refinement could unlock greater value.

The result is not an endpoint but a foundation to:

  • Test different market scenarios and patient behaviors
  • Identify where digital access or behavioral interventions can amplify performance
  • Refine launch and commercialization strategy

For tailored interpretation, Acumetis experts can help transform your readiness score into a targeted, actionable roadmap.

From exploration to decision‑ready clarity

Direct‑to‑patient models can create opportunity, but only when applied with a clear understanding of fit, trade‑offs, and long‑term implications. The Acumetis direct‑to‑patient readiness assessment helps teams move from initial interest to informed decision‑making, grounded in connected insight and practical judgment.

Reframe what’s possible through direct model approaches. Take our direct‑to‑patient readiness assessment to understand whether a DTP approach fits your asset and access strategy.

Start the Assessment →   DTP Readiness Assessment

 

Request a Consultation

Our experts can help you reframe what’s possible. 

Let's Talk

"*" indicates required fields

Learn More

Meet the Experts:

Ali Soroush
Manager, Global Innovation

Ali has deep expertise in corporate and product strategy, launch planning, and commercial analytics. He partners with executive and senior leadership teams to instill an enterprise mindset and strengthen launch and commercialization capabilities. Ali has led successful launches across oncology, immunology, dermatology, CNS, and rare diseases, leveraging advanced analytics to uncover HCP and patient insights that drive performance. He has also developed CRMs and executive dashboards for leading pharma clients to enable data-driven decision-making.

Will Sargent
Will Sargent, MBA
Principal, Global Innovation Lead

Will is experienced in brand planning, business case development, digital strategy, launch planning (diabetes, obesity, oncology, rare diseases), partnership integration, and unbranded / market development. He has experience installing operational best practices and supporting executive strategy, his industry experience includes participating in 16 product launches, medical devices companies, as well as small biotech launching their first commercial products. He has experience in oncology, diabetes, CNS, pain, rare diseases, digital health and connected devices.

Swathi Rangan
Swathi Rangan
Partner, Commercial Strategy Practice Lead

Swathi excels at leading teams to deliver effective, client-centered commercial solutions. She has worked across large, mid-size, and start-up organizations, with deep expertise in immunology, oncology, cardiometabolic disorders, and rare disease. Her experience spans strategy through implementation, with a focus on data- and insight-driven innovation, including patient support and experience design, digital health partnerships, and go-to-market strategy. She also specializes in market-shaping strategies for complex diseases and has successfully led numerous product launches.

FAQs for DTP readiness assessment

What is the DTP readiness assessment Tool?

A self-guided diagnostic that evaluates your product’s readiness for direct-to-patient engagement across four key pillars.

Who should use this tool?

Commercial, access, and brand teams assessing DTP potential for new or existing therapies.

How long does it take?

Approximately 3–5 minutes to complete.

How is the score calculated?

Your responses are benchmarked against industry data and weighted across four readiness pillars.

What happens after I receive my score?

You can download a results summary and request a consultation to explore implications and next steps with our experts.